News Quantified

IPHA – innate pharma s.a. - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 [Yahoo! Finance]

Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026

Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026

Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event [Yahoo! Finance]

Top News Gainers

4/24 Innate Pharma Files Its 2019 Universal Registration Document (Document d’enregistrement universel) and Its 2019 Annual Report on Form 20-F 15.1%

1/2 The European Medicines Agency Accepts the Regulatory Submission for Lumoxiti in Relapsed or Refractory Hairy Cell Leukemia 13.4%

4/14 Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 19, 2020 Without the Physical Presence of Its Shareholders 6.8%

3/10 Innate Pharma reports FY results [Seeking Alpha] 6.5%

3/3 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 3.8%

1/31 INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm 3.0%

2/26 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 2.3%

11/6 Innate Pharma announces preclinical data presentations at SITC 2019 2.2%

11/7 Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting 2.2%

1/13 French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides 2.0%

Top News Decliners

3/14 Innate Pharma SA (IPHYF) CEO Mondher Mahjoubi on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.6%

4/23 Innate Pharma S.A. (NASDAQ: IPHA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.8%

1/9 Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial -10.0%

1/2 Innate Pharma's stock rallies 23% on leukemia drug submission in Europe [MarketWatch] -7.6%

12/13 Innate Pharma Provides Update on Lacutamab TELLOMAK Trial -4.4%

2/14 Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.3%

1/29 EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Innate Pharma S.A. – IPHA -3.3%

11/13 Innate Pharma third quarter 2019 report -3.1%

12/8 Innate Pharma Highlights FDA-Approved Lumoxiti® at ASH 2019 -3.1%

10/21 Innate Pharma Announces Closing of Global Offering -3.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day